secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0000950170-25-099891
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam: Obicetrapib significantly reduces p-tau217 in ApoE4 carriers in BROADWAY
--------------------------------------------------------------------------------

- p-tau217 reduced in full analysis set (p=0.0019, n=1,515) and ApoE4 carriers (p=0.0215, n=367).
- ApoE4/E4 carriers showed 20.48% mean p-tau217 reduction vs placebo (p=0.010).
- Favorable trends observed in NFL, GFAP, p-tau181, and Aβ42/40 biomarkers.
- Safety in BROADWAY overall was comparable to placebo; AD analysis not independently evaluated.
- Company plans to discuss results with regulators and explore next steps for AD program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025099891/0000950170-25-099891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025099891/nams-20250730.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-099891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer